In the case of gliomas, genomic profiling can identify specific genetic alterations in the PI3K pathway, such as gain-of-function mutations in the PIK3CA gene or loss of the tumor suppressor PTEN. This evidence concerns the gene PIK3CA and central nervous system cancer.